The follow-up results are presented for the radiotherapeutic treatment
of 49 patients with uveal eye melanoma using ruthenium-106 (Ru-106/Rh
-106) applicators. Graded doses were applied and the degree of regress
ion was found to be correlated with the dose at the top of the tumour.
Complete regression is found in 66% of the patients treated with a to
p dose above 150 Gy, in which case the initial tumour prominence dimin
ishes in about three years to a stable disease or to a flat scar. At t
his dose a marginal increase in complications was observed as compared
with lower dose groups. Useful vision could be preserved in 75% of th
e eyes.